Nirmatrelvir and molnupiravir reduced the risk of developing post-Covid syndrome


The risk of developing post-Covid syndrome in elderly patients was reduced during therapy with nirmatrelvir and molnupiravir compared with no treatment. A higher risk of developing post-Covid syndrome was found in women and people with low incomes.

Researchers from the US National Institutes of Health (NIH) assessed the effectiveness of nirmatrelvir and molnupiravir in the prevention of post-Covid syndrome in elderly patients. The study results were published in the journal JAMA Internal Medicine.

Nirmatrelvir reduced the risk of developing post-Covid syndrome by 13%, molnupiravir by 8% compared with no treatment. A higher risk of developing post-Covid syndrome was observed among women and people with low incomes. Caucasians were at lower risk. The most common symptoms of post-Covid syndrome were fatigue (29.9%), shortness of breath (22.4%) and cough (21%).




Data from more than 2 million outpatients aged 65 years and older diagnosed with COVID-19 during 2022 were analyzed. Of these, 19.5% received nirmatrelvir, 2.6% received molnupiravir. The incidence of post-Covid syndrome among patients receiving nirmatrelvir was 11.8%, in the molnupiravir group – 13.7%, and in other patients – 14.5%.

The authors noted that nirmatrelvir and molnupiravir are approved to prevent severe acute coronavirus infection. According to scientists, both drugs can be used to prevent the development of post-Covid syndrome.



Source link